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Epithelial tight junctions recruit different types of signalling
proteins that regulate cell proliferation and differentiation. Little
is known about how such proteins interact functionally and
biochemically with each other. Here, we focus on the Y-box
transcription factor ZONAB (zonula occludens 1-associated
nucleic-acid-binding protein)/DbpA (DNA-binding protein A)
and the Rho GTPase activator guanine nucleotide exchange
factor (GEF)-H1/Lbc’s first cousin, which are two tight-junction-
associated signalling proteins that regulate proliferation. Our
data show that the two proteins interact and that ZONAB
activity is Rho-dependent. Overexpression of GEF-H1 induces
accumulation of ZONAB in the nucleus and activates transcrip-
tion. Microtubule-affinity regulating kinase/partition-defective-1,
another type of GEF-H1-associated signalling protein, remains
in the cytoplasm and partially co-localizes with the exchange
factor. GEF-H1 and ZONAB are required for expression of
endogenous cyclin D1, a crucial RhoA signalling target gene,
and GEF-H1-stimulated cyclin D1 promoter activity requires
ZONAB. Our data thus indicate that GEF-H1 and ZONAB form
a signalling module that mediates Rho-regulated cyclin D1
promoter activation and expression.
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INTRODUCTION
Intercellular junctions regulate epithelial cell proliferation
and differentiation using different signalling mechanisms. Tight
junctions, the most apical component of the epithelial junctional
complex, recruit signalling proteins such as protein kinases,
Rho GTPase regulators and transcription factors that can localize
to junctions as well as to nuclei (Aijaz et al, 2006). However, there
is little understanding of how the different junction-associated
signalling molecules are interconnected and coordinate
cellular responses.
ZONAB (zonula occludens 1 (ZO-1)-associated nucleic-acid-
binding protein)/DbpA (DNA-binding protein A) is a Y-box
transcription factor that is recruited to tight junctions by binding
to the Src homology 3 domain of ZO-1 (Balda & Matter, 2000).
ZONAB regulates epithelial proliferation by restricting G1–S
phase progression (Balda et al, 2003). Its transcriptional activity
is important for this regulation because one of the target genes
of ZONAB is cyclin D1, which is a key cell-cycle regulator
(Sourisseau et al, 2006). As ZO-1 binding to ZONAB results in
inhibition, tight junction formation suppresses this proliferation-
promoting pathway. The reported deregulated expression of ZO-1
and ZONAB in different tumours might, therefore, contribute to
the transformed phenotype (Hoover et al, 1998; Martin et al,
2004; Yasen et al, 2005). Binding of activated RalA also inhibits
transcriptional activation of ZONAB (Frankel et al, 2005). By
contrast, the mechanisms that mediate ZONAB activation are poorly
understood: Apg-2, a heat-shock protein, can stimulate ZONAB
activation indirectly by binding to ZO-1 (Tsapara et al, 2006); but
mechanisms that activate ZONAB directly are not known.
Another tight-junction-associated signalling component that
promotes G1–S phase progression is guanine nucleotide exchange
factor (GEF)-H1/Lfc (Benais-Pont et al, 2003; Aijaz et al, 2005).
GEF-H1 is an exchange factor for RhoA, and it has been proposed
that its deregulation contributes to carcinogenesis (Birkenfeld
et al, 2008). In epithelial cells, GEF-H1 activates RhoA signalling,
regulating paracellular permeability, junctional dynamics and
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1125proliferation (Benais-Pont et al, 2003; Aijaz et al, 2005; Ivanov
et al, 2005). Rho GTPases are central regulators of signalling
pathways that guide cell proliferation and differentiation. RhoA
signalling regulates G1–S phase transition, and one of the crucial
target genes of Rho signalling during this cell-cycle step is the
cyclin D1 gene (Coleman et al, 2004; Ridley, 2004). However, if
and how GEF-H1 participates in the regulation of gene expression
is not known.
Cyclin D1 is upregulated during G1 phase and stimulates G1–S
phase transition by binding and activating cyclin-dependent
kinases 4/6, which contributes to cyclin E–CDK2 activation and
inactivation of the cell-cycle inhibitory function of retinoblastoma
protein (pRb) by hyperphosphorylation (Fu et al, 2004). Cyclin D1
also has a role during other cell-cycle phases that require careful
regulation of localization and degradation by phosphorylation
and the ubiquitin/proteosome system (Sherr, 2002; Gladden &
Diehl, 2005).
Here, we show that two tight-junction-associated signalling
proteins, ZONAB and GEF-H1, form a complex and that
activation of the transcriptional activity of ZONAB is regulated
by Rho. Our results indicate that ZONAB and GEF-H1 form a
signalling module that links a Rho activator to a downstream
signalling effector and mediates Rho-regulated cyclin D1 expression.
RESULTS
GEF-H1 regulates cyclin D1 expression
ZONAB and Rho GTPase signalling regulate G1–S phase
progression and cyclin D1 expression (Balda et al, 2003; Coleman
et al, 2004; Ridley, 2004; Sourisseau et al, 2006). As GEF-H1, a
GEF for RhoA, regulates epithelial cell proliferation (Aijaz et al,
2005), we first tested whether GEF-H1 is also required for cyclin
D1 expression. Our experimental system used Madin–Darby
canine kidney (MDCK) cells, which allow tetracycline-regulated
conditional depletion of ZONAB and GEF-H1 (Fig 1A; Aijaz et al,
2005; Sourisseau et al, 2006). To monitor the expression levels
during G1–S phase progression, cells were arrested in low serum
and then stimulated by adding back serum, which results in
efficient re-entry of MDCK cells into the cell cycle and effective
progression into S phase in 24h (Balda et al, 2003).
Depletion of both ZONAB and GEF-H1 resulted in a strong
reduction in cyclin D1 expression in cells that were stimulated
with serum after synchronization in low serum (Fig 1). Depletion of
GEF-H1 did not affect the expression of ZONAB. Overexpression of
both proteins stimulated cyclin D1 expression (Fig 1C,D). Over-
expression of GEF-H1, but not ZONAB, was sufficient to stimulate
increased cyclin D1 levels in arrested cells (0h), indicating that
ZONAB requires serum stimulation for activity. In confluent cells,
expression of cyclin D1 was low in all cell lines (supplementary
Fig S1 online). These data show that GEF-H1 regulates cyclin D1
expression in proliferating cells and, similarly to ZONAB, is
required for serum-induced cyclin D1 upregulation.
GEF-H1 and ZONAB form a complex
GEF-H1 and ZONAB associate with tight junctions but are also
found at other subcellular locations in epithelial cells (Balda &
Matter, 2000; Benais-Pont et al, 2003). By immunofluorescence,
the two proteins co-localize with ZO-1 at intercellular junctions,
indicating that the two proteins might exist in a complex (supple-
mentary Fig S2 online). Therefore, we tested whether GEF-H1 and
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Fig 1 |Regulation of cyclin D1 expression by GEF-H1. (A) MDCK cells
allowing the tetracycline-regulated depletion of GEF-H1 or ZONAB
expression were cultured with the antibiotic for 3 days. Expression
of GEF-H1, ZONAB (marked are the two ZONAB isoforms A and B)
and, as a loading control, a-tubulin was analysed by immunoblotting.
(B,C) The indicated cell lines were cultured for 3 days as in (A), but
by reducing the serum to 0.1% for the last 40h. Serum was then added
back for 24h (B), or for 0h and 12h (C). Expression of cyclin D1 and
of the indicated control proteins was then analysed by immunoblotting
total cell extracts (GEF-H1-VSV, cells expressing VSV-tagged GEF-H1;
ZONABoe, cells overexpressing ZONAB). (D) Immunoblots from three
independent experiments were analysed by densitometry to quantify
cyclin D1 expression after different periods of serum stimulation.
(Shown are means±1s.d., asterisks mark all values with Po0.05
in t-tests). GEF-H1, guanine nucleotide exchange factor-H1; MDCK,
Madin–Darby canine kidney; RNAi, RNA interference; VSV, vesicular
stomatitis virus; ZONAB, zonula occludens 1-associated nucleic-acid-
binding protein.
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1126ZONAB form a complex in MDCK cells by using immunoprecipita-
tion and by monitoring co-precipitation through immunoblotting.
Fig 2A shows that GEF-H1 was detected in ZONAB but not
in control immunoprecipitates. Similarly, ZONAB was detected
in precipitates with GEF-H1-specific antibodies, although
co-precipitation was less efficient. Co-precipitation of GEF-H1
was seen in confluent, but not in proliferating, subconfluent cells
that had been cultured for 2 days, indicating that the complex
does not exist constitutively (Fig 2B). Similarly, GEF-H1 is less
junctional in low confluent than in confluent cells (supplementary
Fig S3 online). These data indicate that GEF-H1 and ZONAB can
form a complex in epithelial cells and that complex formation
depends on cell confluence.
Glutathione S-transferase (GST) fusion proteins containing
different domains of GEF-H1 were then used to map the binding
site for ZONAB (Fig 2C; Aijaz et al, 2005). Pull-down experiments
with MDCK cell extracts revealed that the C1 domain is sufficient
to mediate the interaction with ZONAB (Fig 2D). ZONAB is
expressed in two isoforms, ZONAB-A and -B, and both could
be pulled down efficiently with the C1 fusion protein from
extracts of COS-7 cells transfected with vesicular stomatitis virus
(VSV)-tagged ZONAB isoforms (Fig 2E). As both ZONAB-A and -B
co-immunoprecipitated with GEF-H1, both seem to be able to
form a complex with the exchange factor.
We then used recombinant His-tagged ZONAB to determine
whether the interaction could be reconstituted in vitro. Fig 2F,G
shows that recombinant ZONAB was precipitated by glutathione
S-transferase (GST)-C1 but not GST alone, indicating that the C1
domain of GEF-H1 can bind directly to ZONAB. ZONAB is thus
far the only GEF-H1-interacting protein known to interact with
GST-C1, as other proteins require different or further domains (for
example, microtubule-affinity regulating kinase/partition-defective-1
(MARK/Par1) needs an additional intervening domain; supple-
mentary Fig S4 online).
GEF-H1 stimulates ZONAB activity
Our next step was to ask whether GEF-H1 can stimulate ZONAB
activity. As overexpression of GEF-H1 is sufficient to stimulate
RhoA activation (Birkenfeld et al, 2008), we first tested whether
overexpression stimulates nuclear translocation of ZONAB.
Fig 3 shows that overexpression of GEF-H1 did result in nuclear
accumulation of ZONAB. The remaining cytoplasmic, dotty
staining often seemed to follow the cytoplasmic GEF-H1 staining.
GEF-H1 was no longer detected at junctions but, as indicated in
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Fig 2 |Association of ZONAB with GEF-H1. (A) MDCK cells grown for 4 days were extracted, and GEF-H1 and ZONAB were immunoprecipitated.
The immunoprecipitates were analysed by immunoblotting for ZONAB and GEF-H1. The input lane corresponds to 10% of the extract used for the
immunoprecipitations. (B) Subconfluent (grown for 2 days) and confluent (grown for 7 days) MDCK cells were extracted and subjected to ZONAB
immunoprecipitation. Precipitation of GEF-H1 and ZONAB was then monitored by immunoblotting. Duplicates generated from separate lysates for
each culture condition are shown. (C) Domain structure of GEF-H1. The C1 domain, the ID, DH, PH and CTD are shown. (D) MDCK cell extracts
were incubated with GST fusion proteins containing the indicated GEF-H1 domains bound to glutathione beads. After washing, the pull-downs were
analysed for the presence of ZONAB by immunoblotting. Extracts of COS-7 cells transfected with cDNAs encoding (E) VSV-tagged ZONAB isoforms
(indicated as A and B) or (F) recombinant ZONAB were incubated with beads containing GST or GST–C1 fusion protein. Pull-down was monitored
by immunoblotting. (G) Immunoblot with anti-GST antibodies of fusion proteins used in pull-downs. cDNA, complementary DNA; CTD, C-terminal
domain; DH, Dbl homology domain; GEF-H1, guanine nucleotide exchange factor-H1; GST, glutathione S-transferase; IB, immunoblotting; ID,
intervening domain; MDCK, Madin–Darby canine kidney; PH, pleckstrin homology domain; VSV, vesicular stomatitis virus; ZONAB, zonula
occludens 1-associated nucleic-acid-binding protein.
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1127existing reports (Birkenfeld et al, 2008), was cytosolic and partially
associated with microtubules. MARK/Par1, another GEF-H1 inter-
action partner in MDCK cells that was originally identified in a
proteomics screen (Brajenovic et al, 2004), also dissociated from cell–
cell contacts on GEF-H1 overexpression, but remained cytoplasmic
and partially co-localized with GEF-H1 (Fig 3C and supplementary
Fig S4 online). Induction of GEF-H1 expression induced nuclear
translocation of ZONAB without affecting the expression levels of
ZONAB and ZO-1 (supplementary Fig S5 online).
We next analysed whether Rho signalling and GEF-H1 regulate
the transcriptional activity of ZONAB. We used a reporter gene assay
based on two minimal promoters—one driving firefly luciferase
expression and the other driving renilla luciferase expression—that
differ only by the presence of a ZONAB binding site in one of
them (Frankel et al, 2005). ZONAB functions as a repressor of
the promoter with a functional ZONAB binding site (Balda &
Matter, 2000). Expression of dominant-negative RhoA (T19N-RhoA)
stimulated the ZONAB-responsive promoter, reflecting ZONAB
inhibition (Fig 4A). Accordingly, a constitutively active form
(V14-RhoA) increased ZONAB activity, and incubation with
membrane-permeable C3 transferase—which inactivates RhoA,
B and C—reduced ZONAB activity. As ZONAB is active in low-
density, proliferating cells, but not in high-density cells, promoter
stimulation reflecting ZONAB inactivation was observed only in
low-density cultures. Therefore, the transcriptional activity of ZONAB
is regulated by Rho signalling.
Overexpression of GEF-H1 also repressed the promoter,
indicating ZONAB activation (Fig 4B). Stimulation did not require
the C1 domain, which binds to ZONAB, but overexpression of an
active exchange factor domain was sufficient, as expected from
the constitutively active RhoA mutant result. This indicates that a
direct interaction is not required for regulation when active RhoA
levels are very high (that is, expression of constitutively active
GEF or RhoA). However, depletion of GEF-H1 inhibited ZONAB
activity in low-density cells to a similar extent as did ZONAB
depletion, indicating that GEF-H1 is a functionally relevant
ZONAB activator (Fig 4C). Expression of the ZONAB-interacting
C1 domain inhibited the transcription factor in low-density cells,
indicating that it functions as a dominant mutant. As the C1
domain co-localized with endogenous ZONAB but did not affect
nuclear accumulation, inhibition might have been due to its
prevention of another interaction required for transcription
(supplementary Fig S6 online). In addition, expression of the C1
domain did not affect the distribution of GEF-H1 (supplementary
Fig S7 online).
ZONAB RNA interference (RNAi) was then combined with the
constitutively active GEF-H1 mutant to confirm the involvement of
ZONAB in the changes observed in promoter activation. Fig 4D
shows that in high-density cells, in which ZONAB is not active,
constitutively active GEF-H1 only repressed the promoter in the
presence of ZONAB (with or without co-transfection of a control
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Fig 3 |GEF-H1-induced nuclear accumulation of ZONAB. Wild-type
cells and a line for tetracycline-regulated expression of VSV-tagged
GEF-H1 (GEF-H1–VSV) were incubated with or without the antibiotic
as indicated. The cells were then processed for immunofluorescence by
using antibodies against (A) ZONAB and GEF-H1, (B) ZONAB and ZO-1
(the overlay includes a DNA stain to label the nuclei), and (C) MARK/
Par1 (mAb), GEF-H1–VSV (by using an antibody against VSV) and ZO-1
(included in the overlay in blue). Epifluorescence images for all stains
and a further confocal image in (A) (lower row) are shown. GEF-H1,
guanine nucleotide exchange factor-H1; mAb, monoclonal antibody;
MARK, microtubule-affinity regulating kinase; Tet, tetracycline; VSV,
vesicular stomatitis virus; wt, wild type; ZONAB, zonula occludens 1
(ZO-1)-associated nucleic-acid-binding protein.
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This confirms the requirement of ZONAB for repression of the
promoter by GEF-H1.
ZONAB and GEF-H1 regulate expression of cyclin D1 (Fig 1).
To determine whether this involves changes in cyclin D1
promoter activity, we used a firefly luciferase reporter construct
containing a full-length cyclin D1 promoter with a ZONAB
binding site at position  530 (Albanese et al, 1995; Sourisseau
et al, 2006). Fig 4E shows that this promoter was stimulated by
overexpression of GEF-H1. However, when the ZONAB RNAi
plasmids were co-transfected, stimulation was strongly reduced.
Co-transfection of the control RNAi plasmid did not influence the
promoter. ZONAB is thus required for GEF-H1-stimulated cyclin
D1 promoter activation.
DISCUSSION
Epithelial junctions recruit various signalling proteins,
and several of them are thought to regulate proliferation
and differentiation. Unravelling the biochemical and functional
networks that these proteins form is therefore important
in order to understand the signalling mechanisms they are
involved in. The data presented here show that GEF-H1
and ZONAB form a signalling module that mediates
Rho-stimulated transcription.
The transcriptional activity of ZONAB is Rho-regulated as both
dominant-negative RhoA and C3 transferase inhibit its activity.
How Rho activation stimulates ZONAB is not yet clear. Inhibition
of Rho signalling by inhibition of Rho-associated kinase
(ROCK) and myosin, or transfection of dominant-negative Dia,
did not inhibit ZONAB activity (data not shown). We could not
find evidence for direct binding of ZONAB to RhoA. Therefore,
it might be that a yet-to-be-identified Rho effector stimulates
ZONAB activation. Alternatively, it is possible that inactive
GEF-H1 and ZONAB form a complex in the absence of a
stimulus that localizes at tight junctions and is thus primarily
observed in confluent cultures. GEF-H1-mediated Rho activation
then leads to a dissociation of the complex and, hence, activation
of ZONAB. Given the absence of GEF-H1 from junctions in
overexpressing cells, Rho activation might also lead to an
inactivation of the mechanisms that recruit GEF-H1 complexes
to the junction.
GEF-H1 has already been linked to Rho/ROCK/myosin-
regulated junctional dynamics and dissociation (Aijaz et al,
2006; Samarin et al, 2007). It thus seems that GEF-H1 functions
as a junction-associated Rho signalling hub that activates Rho
and, subsequently, different Rho effector pathways that then drive
junctional rearrangements as well as transcriptional responses.
Recently, GEF-H1 has also been found to be activated in response
Plasmid control
Plasmid control
Plasmid control
Plasmid control
Plasmid control
GEF-H1
Control RNAi
Control RNAi
Control RNAi
ZONAB RNAi
ZONAB RNAi/GEF-H1-CA
Control RNAi/GEF-H1-CA
GEF-H1 RNAi
ZONAB RNAi
ZONAB RNAi
GEF-H1
GEF-H1-CA
C1
–50 50 100 150 0
50 100 150 200 250 0
–60 –40 –20 0 20
Promoter activity
Cyclin D1 promoter activity
Promoter activity
MDCK
GEF-H1–VSV
DeltaC1-GEF-H1
DeltaC1-GEF-H1
GEF-H1-CA
C1
–80 –60 –40 –20 0 20
Promoter activity
V14 RhoA
C3-transferase
High density
Low density
–40 –20 02 0 4 0 6 0
Promoter activity
High density
Low density
High density
T19N RhoA
A
B
C
D
E
Fig 4 |Rho- and GEF-H1-regulated ZONAB activation. (A–D) Low- and
high-density MDCK cells were transfected with the ZONAB reporter
firefly luciferase construct and the control reporter driving renilla
luciferase expression. The used promoter is repressed by ZONAB;
therefore, decreased promoter activity reflects increased ZONAB activity.
As indicated, expression and RNAi plasmids were co-transfected. In (A),
C3-transferase refers to samples that were incubated with recombinant
TAT–C3 fusion protein. After measuring the two luciferase activities,
firefly to renilla luciferase ratios were calculated and changes in
percentages compared with control plasmid transfections were calculated.
(E) Wild-type or GEF-H1–VSV-expressing MDCK cells were plated at
high density and transfected with a cyclin D1 promoter/firefly luciferase
and a control promoter/renilla luciferase construct together with the
indicated RNAi plasmids. The cells were then assayed as above and
the cyclin D1 promoter activity, normalized by the measured renilla
luciferase activities, was expressed relative to wild-type MDCK cells
transfected with a control plasmid. All values represent averages of
three independent experiments performed in triplicate. GEF-H1, guanine
nucleotide exchange factor-H1; GEF-H1-CA, constitutively active GEF-H1;
MDCK, Madin–Darby canine kidney; RNAi, RNA interference; VSV,
vesicular stomatitis virus; ZONAB, zonula occludens 1-associated
nucleic-acid-binding protein.
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1129to inflammatory stimuli (Fukazawa et al, 2008; Kakiashvili et al,
2009), which is also observed in MDCK cells (supplementary
Fig S8 online). However, at least one such stimulator, TNFa, does
not stimulate the transcriptional activity of ZONAB (data not
shown), suggesting that additional signalling mechanisms act on
ZONAB to modulate its activation. One possibility is that RalA
binding inhibits TNFa-induced ZONAB activation: RalA binds
to and inhibits ZONAB and is activated in response to TNFa
(Sugihara et al, 2002; Frankel et al, 2005).
Rho signalling regulates transcription of genes by different
mechanisms. Perhaps the best studied one is the regulation of
serum response factor, a transcription factor that is activated
by a co-activator in which nuclear accumulation is regulated
by Rho GTPases through actin polymerization (Miralles et al,
2003). Another type of Rho regulation is represented by NF-kB, a
transcription factor that is modulated by Rho GTPases and
Rho kinases either directly or indirectly by phosphorylation
of upstream regulators (Perkins, 2007). To our knowledge,
ZONAB is the first case of a Rho-regulated transcription
factor that associates with a Rho GEF. Thus, GEF-H1 and ZONAB
form a new type of signalling module that spatially links
a Rho activator to an effector pathway to transmit signals to
the nucleus.
METHODS
Cell lines, expression constructs, RNAi and antibodies. MDCK
cells for tetracycline-regulated GEF-H1 expression, and RNAi of
GEF-H1 and ZONAB were described previously (Aijaz et al, 2005;
Sourisseau et al, 2006). GEF-H1 constructs fused to VSV and GST
were described by Aijaz et al (2005) and ZONAB expression and
RNAi plasmids by Balda et al (2003). The cDNAs encoding the four
HA-tagged MARKs were provided by Gerard Drewes (Cellzome
AG, Heidelberg, Germany). See supplementary information online
for a list of antibodies used.
Immunofluorescence and protein analysis. Fixation with metha-
nol, and processing and analysis of cells for immunofluorescence
were performed as described (Balda et al, 2003). Immunopreci-
pitations, immunoblotting, fusion protein production and pull-
down assays were described by Aijaz et al (2005). Recombinant
C-TAK1 was from Millipore (Billerica, MA, USA). See supple-
mentary information online for sources of antibodies used and
details of protein analysis, including cell culture.
Reporter assays. MDCK cells were plated into 96-well dishes at a
low (2,000cells/well) or high (12,000cells/well) concentration the
day before transfection. To measure ZONAB activity, two
plasmids were co-transfected using the calcium phosphate
method: one with a minimal promoter with a ZONAB binding
site driving firefly luciferase expression, and the other with an
identical promoter but with a mutant ZONAB binding site driving
renilla luciferase expression (Balda & Matter, 2000; Frankel et al,
2005). All expression and RNAi plasmids that were co-transfected
were mixed with the reporter plasmids before forming the
precipitate; total DNA concentrations were kept constant with
empty vectors. After 2 days, the two luciferases were measured
sequentially using the dual luciferase assay kit (Promega Corp,
Madison, WI, USA). The activity of the cyclin D1 promoter was
assayed as described previously (Sourisseau et al, 2006).
Supplementary information is available at EMBO reports online
(http://www.emboreports.org).
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